[Br:1][C:2]1[CH:3]=[C:4]([CH:8]2[NH:12][C:11](=[O:13])[CH2:10][CH2:9]2)[CH:5]=[N:6][CH:7]=1.[H-].[Na+].[CH3:16]I>C1COCC1>[Br:1][C:2]1[CH:3]=[C:4]([CH:8]2[NH:12][C:11](=[O:13])[CH2:10][CH2:9]2)[CH:5]=[N:6][CH:7]=1.[Br:1][C:2]1[CH:3]=[C:4]([CH:8]2[N:12]([CH3:16])[C:11](=[O:13])[CH2:10][CH2:9]2)[CH:5]=[N:6][CH:7]=15-(5-Bromo-pyridin-3-yl)-pyrrolidin-2-one is prepared as described in Example 76. To a solution of 5-(5-bromo-pyridin-3-yl)-pyrrolidin-2-one (202 mg, 0.84 mmol) in THF (5.0 mL) is added 60% NaH (50 mg, 1.3 mmol). The mixture is stirred at room temperature for 5 min and methyl iodide (0.078 mL, 1.3 mmol) is then added dropwise. The mixture is stirred at room temperature for 16 h. The mixture is then concentrated and purified by normal phase chromatography to give 157 mg of 5-(5-bromo-pyridin-3-yl)-1-methyl-pyrrolidin-2-one.
読み込み中…
